An aging body is like an orchestra in which some instruments start playing louder than they should. The conductor's podium here is mTORC1, a protein complex that governs cell growth and metabolism. With age, its signals drift, and in response to ordinary triggers the immune system mounts an overly strong inflammatory reaction. Rapamycin, a drug that inhibits mTORC1, has been tried as a tuner that quiets the instruments that have gotten out of hand. But for a long time it remained unclear whether it would also muffle the useful sounds along with the noise, that is, whether it might cause dangerous immune suppression.
To test this, old mice were fed chow with microencapsulated rapamycin for five months. The dose was low, just 14 parts per million in the feed, corresponding to roughly 2.24 milligrams per kilogram of body weight per day. The control group received the same chow with empty capsules. The scientists then counted immune cells in blood, bone marrow, spleen, lymph nodes and the abdominal cavity. It turned out that the orchestra's lineup had not changed: the share of monocytes, neutrophils and B cells remained the same. Among T cells there was only a slight shift toward memory cells, which agrees with earlier data.
Then a separate group of mice was given lipopolysaccharide, a bacterial component that triggers inflammation. Four hours later, the animals on rapamycin had significantly lower levels of the inflammatory signals IL-12p40, IL-17A and IL-27 in their blood. In the brain, in microglia, the cells that serve as immune defenders there, the activity of the inflammatory genes Tnf-α, Il6 and Tlr2 dropped. Yet at rest, without a bacterial stimulus, the levels of these signals did not differ from controls. So the tuner left the quiet instruments alone and only turned down those that were starting to sound too loud in alarm.
Previously it was unclear whether long-term mTORC1 inhibition in old animals would cause dangerous immunosuppression. Now it is clear that a five-month low-dose rapamycin diet does not change the makeup of major immune cells, but it does reduce the age-related accumulation of IL-17-producing gamma-delta T cells and blunts microglia's response to a bacterial stimulus. This shifts the focus from the question "does rapamycin suppress immunity" to the question "which signals exactly does it retune."
This safety profile keeps interest alive in rapamycin as a potential geroprotector. But the question remains open as to exactly how signals from peripheral gamma-delta T cells change microglial reactivity. Perhaps interleukin-17 acts directly on microglial receptors, or the effect is mediated by the gut microbiome through the gut-brain axis. If this is confirmed, new targets will emerge for drugs that slow aging without heavy-handed intervention. The tuner is still learning to tell the instruments apart, but it is already clear that it can work with a light touch.
Rapamycin was discovered in a soil sample from Easter Island and named after the island's local name, Rapa Nui. It was first used as an antifungal, and its immunosuppressive properties were discovered later.
The idea of a drug that slows aging without breaking the body echoes the motif of a 'soft' geroprotector from Bruce Sterling's novel Schismatrix, where life extension is achieved through fine-tuning biology rather than blunt intervention.
Not published on arXiv. Here are its page, the PDF and the formalization: you can check it yourself, not only read our account.